Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortTablet that blocks inflammation signals for arthritis and colitis.Biologic injection for arthritis, IBD and psoriasis.
Body systemJoints & ImmunityJoints & Immunity
Drug classJAK inhibitorsTNF inhibitors
SupplyPrescription onlyPrescription only
Main usesRheumatoid arthritis, Psoriatic arthritis, Ulcerative colitis, Ankylosing spondylitisRheumatoid and psoriatic arthritis, Ankylosing spondylitis, Crohn's disease and ulcerative colitis, Psoriasis, Hidradenitis suppurativa
How it worksBlocks the relay inside immune cells that passes on inflammation signals.Mops up a key inflammation signal.
Starts working——
Half-lifeAbout 3 hoursAbout 2 weeks
Typical adult dose5 mg twice a day (10 mg twice a day for induction in ulcerative colitis).40 mg under the skin every other week (some conditions start higher or go weekly).
FormsTablet, Modified-release tablet, Oral solutionPre-filled pen, Pre-filled syringe
Common side effectsCold-like infections, Headache, Diarrhoea, Raised cholesterolInjection-site reactions, Upper respiratory infections, Headache
Serious side effectsShingles, Blood clots, Heart attacks and cancer in at-risk groups, Serious infectionsSerious infections including TB reactivation, Lymphoma (rare), Demyelination, Heart failure worsening
Don't take if——
Alcohol——
PregnancyUsually avoidedNot recommended.Use with cautionOften continued into pregnancy for IBD; baby's live vaccines may be delayed.
Breastfeeding——
In use since20122002
Brand namesUnited States: XeljanzUnited Kingdom: XeljanzIndia: Tofacinix, XeljanzUnited States: Humira, Hadlima, Hyrimoz, YuflymaUnited Kingdom: Humira, Amgevita, Imraldi, YuflymaIndia: Exemptia, Adfrar
Legal status——
ATC code—L04AB04

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker